BIO 2026: Kivu Bioscience exited stealth late last year to develop "kinder and gentler" antibody-drug conjugates with a lower antibody to payload ratio to improve precision and tolerability

53 minutes ago
1 min read

CEO Mohit Trikha describes the idea behind this approach, which in many ways is the opposite of what many ADC developers have been working on. The lead programs target PTK7 and CEACAM5.

https://vimeo.com/1204615580

Coverage brought to you by

Recent Posts

See All

BIO 2026: Nkarta will have key data by the end of the year from its NK cell therapy approach in a host of autoimmune conditions

BIO 2026: COUR Pharma last week raised a $50M series B to progress its nanoparticle approach to reprogramming the immune system to treat type 1 diabetes

BIO 2026: Enveda's AI discovery platform leans heavy on chemistry and learnings from Mother Nature - the lead clinical program to come out of it is focused on atopic derm

BIO 2026: Kivu Bioscience exited stealth late last year to develop "kinder and gentler" antibody-drug conjugates with a lower antibody to payload ratio to improve precision and tolerability

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight